Enveric Biosciences Announced That The U.S. Patent And Trademark Office Issued Patent No. 11,707,441, Titled "C4-carbonothioate-Substituted Tryptamine Derivatives And Methods Of Using"
Portfolio Pulse from Benzinga Newsdesk
Enveric Biosciences has been granted Patent No. 11,707,441 by the U.S. Patent and Trademark Office. The patent covers EB-373, a new chemical entity psilocin prodrug being developed by Enveric for the treatment of anxiety disorder.
August 28, 2023 | 12:05 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Enveric Biosciences has secured a patent for EB-373, a new drug being developed for anxiety disorder. This could potentially strengthen the company's intellectual property portfolio and provide a competitive edge in the market.
The issuance of a patent for a new drug being developed by Enveric Biosciences could potentially enhance the company's value and provide a competitive advantage in the market. This could lead to positive investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100